Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers



Status:Active, not recruiting
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/16/2019
Start Date:August 2015
End Date:August 2019

Use our guide to learn which trials are right for you!

A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

The purpose of this study is to test the safety and effectiveness of albumin-bound paclitaxel
plus gemcitabine in patients with advanced squamous cell lung cancers. The investigators
would like to determine the percentage of patients with squamous cell lung cancers who
experience shrinkage of their tumors following treatment with this regimen. This combination
of drugs is not a standard therapy for patients with squamous cell lung cancers. However,
each of these drugs, when given alone or with other chemotherapies, is FDA-approved for the
treatment of this disease.


Inclusion Criteria:

- Histologically confirmed squamous cell lung cancer

- Newly diagnosed untreated Stage IV and/or recurrent after adjuvant therapy with
metastatic disease

- Patients previously treated with immune checkpoint inhibitor therapy are eligible

- Measurable disease as per RECIST 1.1

- Greater than 6 months since receiving neo-adjuvant or adjuvant chemotherapy.

- Age ≥ 18 years

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

- Women of childbearing potential and sexually active men enrolled in the study must
agree to practice effective contraception method during treatment and for three months
after completing treatment

- Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing
potential

- < Grade 2 pre-existing peripheral neuropathy (per CTCAE)

- Marrow and organ function as follows:

- ANC ≥ 1500 cells/mm3

- Platelets > 100,000 cells/mm3

- Hemoglobin>9g/dL

- Creatinine clearance ≥ 40mL/min

- Bilirubin ≤ 1.5 mg/dL

- AST/ALT≤2.5 x upper limit of normal range (ULN),

- alkaline phosphatase ≤ 2.5 X upper limit of normal, unless bone metastasis in present
in the absence of liver metastasis

Exclusion Criteria:

- Prior treatment with albumin-bound paclitaxel or gemcitabine

- Prior systemic anticancer therapy for advanced squamous cell lung cancer

- Untreated brain metastasis. Patients with treated brain metastases who are off
steroids are eligible

- Peripheral neuropathy greater than grade 1

- Malignancies within the past 5 years other than non-melanoma skin cancer or insitu
cervical cancer status post treatment

- Patients with other serious medical illnesses including, ongoing or active infection,
unstable angina pectoris, or psychiatric illness/social situations that would limit
compliance with study requirements

- Class III or IV congestive heart failure by New York Heart Association
We found this trial at
6
sites
Basking Ridge, New Jersey 07920
Phone: 646-888-4202
?
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Commack, New York 11725
Phone: 646-888-4202
?
mi
from
Commack, NY
Click here to add this to my saved trials
Miami, Florida 33143
Phone: 305-595-2141
?
mi
from
Miami, FL
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Paul Paik, MD
Phone: 646-888-4202
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
Rockville Centre, New York 11570
Phone: 646-888-4202
?
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Sleepy Hollow, New York 10591
Phone: 646-888-4202
?
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials